11 Best Australian Stocks to Buy According to Analysts

Page 7 of 10

4. Immuron Limited (NASDAQ:IMRN) 

Number of Hedge Fund Holders: N/A

Analyst Upside Potential: 161.78%

Immuron Limited (NASDAQ:IMRN) is a biopharmaceutical company that specializes in the development and commercialization of polyclonal antibodies for treating infectious diseases. It operates through two main business segments, including the Research and Development and Hyperimmune Products segments.

The company released its March quarter results for 2025. During the quarter, Immuron Limited (NASDAQ:IMRN) surpassed AUD$5 million in a fiscal year to reach AUD$5.3 million year-to-date as of March 2025. This represented a 46% increase year-over-year, marking the highest sales in the company’s history.

Moreover, on March 5, Immuron Limited (NASDAQ:IMRN) reported that it has entered into a definitive agreement to launch ProIBS in Australia and New Zealand. ProIBS is a certified medical device designed to relieve symptoms associated with Irritable Bowel Syndrome. The CEO of the company emphasized that the ProIBS complements the company’s premium efficacy product range and provides pharmacists with a scientifically backed, physician-recommended option to improve patient outcomes. The company ranks as one of the best Australian stocks to buy according to analysts.

Page 7 of 10